Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Receivables (2024 - 2025)

Crinetics Pharmaceuticals has reported Receivables over the past 2 years, most recently at $8.4 million for Q4 2025.

  • For Q4 2025, Receivables changed 0.48% year-over-year to $8.4 million; the TTM value through Dec 2025 reached $8.4 million, changed 0.48%, while the annual FY2025 figure was $8.4 million, 0.48% changed from the prior year.
  • Receivables for Q4 2025 was $8.4 million at Crinetics Pharmaceuticals, roughly flat from $8.3 million in the prior quarter.
  • Over five years, Receivables peaked at $8.4 million in Q4 2025 and troughed at $8.3 million in Q4 2024.